Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Int J Mol Sci · 2022 · PMC9224277 · PMID 35743140

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

a positive trendp = 0.064so close (0.05 < p ≤ 0.1)

In the gender specific analyses we observed a significant correlation in male NAFLD patients between CCL2 serum levels and advanced fibrosis stages as well as a positive trend for female patients ( p = 0.064).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.